NeuroSense Therapeutics Statistics
Total Valuation
NRSN has a market cap or net worth of $24.18 million. The enterprise value is $24.18 million.
| Market Cap | 24.18M |
| Enterprise Value | 24.18M |
Important Dates
The next estimated earnings date is Friday, July 31, 2026, before market open.
| Earnings Date | Jul 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NRSN has 35.35 million shares outstanding. The number of shares has increased by 36.98% in one year.
| Current Share Class | 35.35M |
| Shares Outstanding | 35.35M |
| Shares Change (YoY) | +36.98% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 33.96% |
| Owned by Institutions (%) | 1.12% |
| Float | 23.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 22.58 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.31
| Current Ratio | 0.31 |
| Quick Ratio | 0.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -2,174.98% and return on invested capital (ROIC) is -1,094.49%.
| Return on Equity (ROE) | -2,174.98% |
| Return on Assets (ROA) | -247.30% |
| Return on Invested Capital (ROIC) | -1,094.49% |
| Return on Capital Employed (ROCE) | 744.96% |
| Weighted Average Cost of Capital (WACC) | 12.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$654,412 |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.31% in the last 52 weeks. The beta is 1.56, so NRSN's price volatility has been higher than the market average.
| Beta (5Y) | 1.56 |
| 52-Week Price Change | -66.31% |
| 50-Day Moving Average | 0.77 |
| 200-Day Moving Average | 0.90 |
| Relative Strength Index (RSI) | 37.08 |
| Average Volume (20 Days) | 175,791 |
Short Selling Information
The latest short interest is 585,034, so 1.65% of the outstanding shares have been sold short.
| Short Interest | 585,034 |
| Short Previous Month | 491,665 |
| Short % of Shares Out | 1.65% |
| Short % of Float | 2.51% |
| Short Ratio (days to cover) | 2.64 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.09M |
| Pretax Income | -11.13M |
| Net Income | -11.13M |
| EBITDA | -11.07M |
| EBIT | -11.09M |
| Earnings Per Share (EPS) | -$0.44 |
Balance Sheet
The company has $166,000 in cash and $170,000 in debt, with a net cash position of -$4,000 or -$0.00 per share.
| Cash & Cash Equivalents | 166,000 |
| Total Debt | 170,000 |
| Net Cash | -4,000 |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | -1.56M |
| Book Value Per Share | -0.05 |
| Working Capital | -1.74M |
Cash Flow
In the last 12 months, operating cash flow was -$7.67 million and capital expenditures -$8,000, giving a free cash flow of -$7.68 million.
| Operating Cash Flow | -7.67M |
| Capital Expenditures | -8,000 |
| Depreciation & Amortization | 16,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.68M |
| FCF Per Share | -$0.22 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRSN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.98% |
| Shareholder Yield | -36.98% |
| Earnings Yield | -46.01% |
| FCF Yield | -31.76% |
Analyst Forecast
The average price target for NRSN is $6.50, which is 850.29% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.50 |
| Price Target Difference | 850.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |